Based on the various affirmations that it would take agreement from one or maybe 2 key sh then Mesoblast is moderately safe from being bought.
The other plus I take heart from is that Mesoblast is not dependent on more capital raising from the market to proceed to market for aGVHD, which should then fund any further requirements for other products all being well until a partner or partners come on board, or not.
On that train of thought, does anyone know if the companies that have gone on to be major players in biopharma started out by partnering with a sales partner?
Thinking Bayer, CSL, Takeda etc, in the time before they started partnering or buying smaller enterprises to gain expertise or access to wider or, more defined markets or their patent suite.
Share price beat down continues, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.0¢ |
Change
0.010(1.02%) |
Mkt cap ! $1.130B | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | $1.02 | 98.5¢ | $5.507M | 5.501M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9996 | 99.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 18069 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |